Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up.

Saved in:
Bibliographic Details
Title: Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up.
Authors: Veerapandiyan, Aravindhan1 (AUTHOR), Bourke, John2 (AUTHOR), Soslow, Jonathan H.3 (AUTHOR), Day, John W.4 (AUTHOR), McDonald, Craig M.5 (AUTHOR), Mendell, Jerry R.6 (AUTHOR), Zaidman, Craig M.7 (AUTHOR), Mason, Stefanie6 (AUTHOR), Meng, Jianfeng6 (AUTHOR), Vivien, Mark6 (AUTHOR), Murphy, Alexander P.8 (AUTHOR), Wandel, Christoph9 (AUTHOR), Richardson, James6 (AUTHOR) jrichardson@sarepta.com
Source: Cardiology & Therapy. Jul2026, p1-17. 17p.
Database: Academic Search Ultimate
Description
ISSN:21938261
DOI:10.1007/s40119-026-00457-5